CSI Market
Sign In | Register

Lava Therapeutics Nv (LVTX) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access LVTX Annual Cash Flow →
The data below summarizes Lava Therapeutics Nv's cash flow activity from Sep 30 2024 to Sep 30 2025, enabling a period-by-period view of cash movement.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Sep 30 2025)
9 Months 		(Jun 30 2025) (Mar 31 2025) (Dec 31 2024) (Sep 30 2024)
Operating Activities
Income-7.19
Depreciation & amortization0.12
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Asset Impairment Charges0.04
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.36
Share-based Compensation1.37
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction-0.17
Adjustments For Depreciation And Amortisation Expense-
Adjustments For Income Tax Expense-
Adjustment For Amortization Of Premium On Investments-
Adjustments For Decrease Increase In Trade And Other Receivables-
Adjustments For Increase Decrease In Value Added Tax Receivable-
Adjustments For Increase Decrease In Trade And Other Payables-
Adjustments For Increase Decrease In Deferred Offering Costs-
Adjustments For Increase Decrease In Contract Liabilities-
Adjustments For Increase Decrease In Research And Development License Liabilities-
Non Cash Operating Lease Expense0.14
Adjustment Foreign Currency Gain Loss0.58
Accrued Interest Income Expenses On Borrowings-
Increase Decrease In Operating Lease Liability-0.14
Increase Decrease In License Liabilities-
Income taxes0.00
Proceeds From Disposal Or Maturity Of Availableforsale Financial Assets0.00
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable-1.26
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities-8.17
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.67
Other Working Capital0.09
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-30.26
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.29
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Proceeds From Sales Of Investments Other Than Investments Accounted For Using Equity Method-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Proceeds from Sale, Maturity and Collection of Investments40.08
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities40.36
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Issue Of Ordinary Shares-
Proceeds From Issue Of Preference Shares-
Payments To Acquire Or Redeem Entitys Shares-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.00
Effect of exchange rate on cash flow4.55
Discontinued operations0.00
Free Cash Flow-29.97
Total Cash Flow10.10
4 historic quarters locked

Sign in to unlock the full Lava Therapeutics Nv cash flow history.

Sign In Create Free Account

About Lava Therapeutics Nv Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001104659-25-107725

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Get the full CSIMarket dataset: Subscribe API License